Protocol Ledger

NCT07023627 · Phase II · RECRUITING

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Interventional Phase II clinical trial protocol NCT07023627 sponsored by Incyte in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-11-12 Enrollment: 160 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07023627
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)160 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07023627
Protocol FieldVerified Registry Value
NCT IdentifierNCT07023627
Consolidated Lead SponsorIncyte
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment160 participants (ESTIMATED)
Registered Start Date2025-11-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Incyte across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI